Healthcare shares knock FTSE after announcement of new U.S. tax rules
Reuters
Published Sep 23, 2014 09:12
Healthcare shares knock FTSE after announcement of new U.S. tax rules
By Francesco Canepa
LONDON (Reuters) - Healthcare shares pushed Britain's main equity index lower on Tuesday as new U.S. tax rules dented the takeover appeal of companies such as Shire (L:SHP) and AstaZeneca (L:AZN) for U.S. suitors.
Market sentiment was also depressed by surveys showing French business activity contracting again in September and Germany's manufacturing sector growing at its slowest pace since June 2013, casting a shadow over the euro zone's recovery prospects.
The U.S. Treasury Department announced new rules, effective immediately, which will reduce the tax benefits available to companies which strike tax "inversion" deals. Such deals allow firms to escape high U.S. taxes by reincorporating abroad.
Britain's more favourable tax regime has been a key factor fuelling U.S. takeover interest in London-listed companies, particularly in the healthcare sector.
Drugmaker Shire, which is being acquired by the United States' AbbVie's (N:ABBV), tumbled 6 percent. AstaZeneca, which turned down a bid from Pfizer (PFE) earlier this year, fell 5 percent and medical devices manufacturer Smith & Nephew Plc (L:SN), also tipped as a U.S. bid target, shed 3.5 percent.
Overall, the healthcare sector knocked 23 points off the FTSE 100 (FTSE), which was down 50.39 points, or 0.7 percent, at 6,723.24 points at 0637 GMT.
The index had closed down 64.29 points on Monday, extending its retreat from this month's 14-1/2 year high of 6,904.86.
"I think we're going to be treading water around here for a bit," said Mark Ward, head of execution trading at Sanlam Securities UK, adding that he saw the index hovering in the 6,720-6,730 area.
"I can see a bit of weakness but I can't see it going through the floor."
Mid-cap sweetener maker Tate & Lyle (L:TATE) fell 16 percent after it said its annual profit would be hit by significant disruption to its supply chain and increased competition for its Splenda sucralose sweetener.
(Reporting By Francesco Canepa; Editing by Gareth Jones)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.